Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) issued its quarterly earnings data on Monday, July 31st. The biopharmaceutical company reported ($0.22) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.33) by $0.11, MarketWatch Earnings reports. Galmed Pharmaceuticals had a negative net margin of 1,443.98% and a negative return on equity of 141.13%. The company had revenue of $0.27 million during the quarter, compared to the consensus estimate of $0.29 million.
Shares of Galmed Pharmaceuticals (NASDAQ GLMD) opened at 7.62 on Friday. The firm’s market cap is $93.11 million. The stock’s 50 day moving average is $7.25 and its 200-day moving average is $5.54. Galmed Pharmaceuticals has a 52-week low of $2.78 and a 52-week high of $8.87.
An institutional investor recently bought a new position in Galmed Pharmaceuticals stock. GRT Capital Partners L.L.C. purchased a new position in shares of Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) during the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor purchased 18,314 shares of the biopharmaceutical company’s stock, valued at approximately $114,000. GRT Capital Partners L.L.C. owned 0.15% of Galmed Pharmaceuticals at the end of the most recent quarter. 7.72% of the stock is currently owned by hedge funds and other institutional investors.
Galmed Pharmaceuticals Company Profile
Galmed Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company. The Company focuses on the development and commercialization of once-daily, oral therapy for the treatment of liver diseases and cholesterol gallstones utilizing its synthetic fatty-acid/bile-acid conjugate (FABAC), called aramchol.
What are top analysts saying about Galmed Pharmaceuticals Ltd.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Galmed Pharmaceuticals Ltd. and related companies.